GER-009-06-AVX Early Therapy in Multiple Sclerosis (FIT)
This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.
Relapsing-Remitting Multiple Sclerosis
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||GER-009-06-AVX Early Therapy in Multiple Sclerosis|
|Study Start Date:||April 2006|
|Study Completion Date:||December 2008|
|Primary Completion Date:||October 2007 (Final data collection date for primary outcome measure)|
This study will address the cognitive dysfunction associated with MS. It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients. Safety data will also be collected during this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00492570
|Principal Investigator:||Biogen-Idec Study Director||Biogen Idec|